Inventor · disambiguated record
Wei Yan
Also filed as: YAN WEI · Yan wei-hua
17 granted patents·28 pending applications·442 citations·filing 2003–2023
93Inventor score
Files withAMGEN INC23QILU PUGET SOUND BIOTHERAPEUTICS CORP9BAYLOR COLLEGE MEDICINE2TAIZHOU ENZE MEDICAL CT GROUP2YAN WEI2
Top patents by PatentIndex Score
45 records- 0196US8592562B2Method for making antibody Fc-heterodimeric molecules using electrostatic steering effectsKANNAN GUNASEKARAN·Filed 2009·Granted Nov 26, 2013·339 cites·18 claims
- 0294US7267960B2Antagonists and agonists of LDCAM and methods of useAMGEN INC·Filed 2004·Granted Sep 11, 2007·42 cites·12 claims
- 0388US9822173B2Heterodimeric immunoglobulinsAMGEN INC·Filed 2013·Granted Nov 21, 2017·10 cites·19 claims
- 0487US11130808B2Mixtures of antibodiesQILU PUGET SOUND BIOTHERAPEUTICS CORP·Filed 2017·Granted Sep 28, 2021·6 cites·21 claims
- 0587US8227251B2Mass spectrum-based identification and quantitation of proteins and peptidesRANISH JEFF·Filed 2010·Granted Jul 24, 2012·13 cites·35 claims
- 0686US10233237B2Heterodimeric immunoglobulinsAMGEN INC·Filed 2013·Granted Mar 19, 2019·8 cites·16 claims
- 0786US8193322B2Methods for generating monovalent IgGYAN WEI·Filed 2006·Granted Jun 5, 2012·19 cites·40 claims
- 0882US11753475B2Bispecific-Fc moleculesAMGEN INC·Filed 2018·Granted Sep 12, 2023·1 cites·8 claims
- 0979US2023212297A1Bispecific fc moleculesAMGEN INC·Filed 2022·Application pending·0 cites
- 1078US11198732B2Fc variantsAMGEN INC·Filed 2019·Granted Dec 14, 2021·1 cites·10 claims
- 1178US11124570B2Anti-PD1 and anti-CTLA4 antibodiesQILU PUGET SOUND BIOTHERAPEUTICS CORP·Filed 2017·Granted Sep 21, 2021·1 cites·12 claims
- 1276US11634502B2Heterodimeric bispecific antibodiesAMGEN INC·Filed 2014·Granted Apr 25, 2023·2 cites·24 claims
- 1373US2023055407A1V-c-fc-v-c antibodyAMGEN INC·Filed 2022·Application pending·0 cites
- 1472US2023077648A1Heterodimeric Bispecific AntibodiesAMGEN INC·Filed 2022·Application pending·0 cites
- 1567US11466078B2Heterodimeric immunoglobulinsAMGEN INC·Filed 2019·Granted Oct 11, 2022·0 cites·7 claims
- 1667US2020071425A1Heterodimeric Bispecific AntibodiesAMGEN INC·Filed 2019·Application pending·0 cites
- 1767US2023212318A1Protease-activatable bispecific proteinsAMGEN INC·Filed 2022·Application pending·0 cites
- 1866US12037397B2Anti-PD1 and anti-CTLA4 antibodiesQILU PUGET SOUND BIOTHERAPEUTICS CORP·Filed 2021·Granted Jul 16, 2024·0 cites·9 claims
- 1963US12441816B2Heterodimeric Fc for making fusion proteins and bispecific antibodiesQILU PUGET SOUND BIOTHERAPEUTICS CORP·Filed 2022·Granted Oct 14, 2025·0 cites·46 claims
- 2063US2016257748A1V-c-fc-v-c antibodyAMGEN INC·Filed 2014·Application pending·0 cites
- 2163US2020040075A1V-c-fc-v-c antibodyAMGEN INC·Filed 2019·Application pending·0 cites
- 2262US2019002568A1Bispecific fc moleculesAMGEN INC·Filed 2018·Application pending·0 cites
- 2362US2016145340A1Bispecific-fc moleculesAMGEN INC·Filed 2014·Application pending·0 cites
- 2462US2014302037A1BISPECIFIC-Fc MOLECULESAMGEN INC·Filed 2014·Application pending·0 cites
- 2561US8043615B2Methods of antagonizing LDCAM and CRTAMAMGEN INC·Filed 2007·Granted Oct 25, 2011·0 cites·6 claims
- 2661US2022073615A1Mixtures of antibodiesQILU PUGET SOUND BIOTHERAPEUTICS CORP·Filed 2021·Application pending·0 cites
- 2760US2025034261A1Monoclonal antibody against hla-g1, -g2, -g5 and hla-g6 isoforms and use thereofTAIZHOU ENZE MEDICAL CT GROUP·Filed 2022·Application pending·0 cites
- 2860US2014308285A1Heterodimeric bispecific antibodiesAMGEN INC·Filed 2014·Application pending·0 cites
- 2958US12496302B2Compositions and methods for the treatment and diagnosis of cancerMASSACHUSETTS GEN HOSPITAL·Filed 2021·Granted Dec 16, 2025·0 cites·18 claims
- 3058US2025289892A1Monoclonal antibody against hla-g1, hla-g4 and hla-g5 isoforms and use thereofTAIZHOU ENZE MEDICAL CT GROUP·Filed 2022·Application pending·0 cites
- 3157US2022267446A1Combinations of anti-pd1 and anti-ctla4 antibodiesQILU PUGET SOUND BIOTHERAPEUTICS CORP·Filed 2022·Application pending·0 cites
- 3255US2023279130A1Anti-ccr8 antibodiesQILU PUGET SOUND BIOTHERAPEUTICS CORP·Filed 2023·Application pending·0 cites
- 3353US2024190903A1Compounds for programmable protein degradation and methods of use for the treatment of diseaseMAYO FOUND MEDICAL EDUCATION & RES·Filed 2022·Application pending·0 cites
- 3453US2015359763A1Use of 3-bromopyruvate as a contraceptiveYAN WEI·Filed 2014·Application pending·0 cites
- 3552US2021023151A1Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Application pending·0 cites
- 3651US2024059785A1Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereofQILU PUGET SOUND BIOTHERAPEUTICS CORP·Filed 2020·Application pending·0 cites
- 3750US2014112926A1Fc VARIANTSLIU ZHI·Filed 2012·Application pending·0 cites
- 3850US2014024111A1Host cell for making antibody fc-heterodimeric molecules using electrostatic steering effectsAMGEN INC·Filed 2013·Application pending·0 cites
- 3949US7232678B2Identification of oligoadenylate synthetase-like genesBAYLOR COLLEGE MEDICINE·Filed 2003·Granted Jun 19, 2007·0 cites·4 claims
- 4048US2016032014A1Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9AMGEN INC·Filed 2014·Application pending·0 cites
- 4148US2008081780A1Identification of oligoadenylate synthetase-like genesBAYLOR COLLEGE MEDICINE·Filed 2007·Application pending·0 cites
- 4248US2024059685A1Piezo1 agonists for the promotion of bone formationBIOVENTURES LLC·Filed 2020·Application pending·0 cites
- 4342US2022235144A1Anti-sirp-alpha antibodiesQILU PUGET SOUND BIOTHERAPEUTICS CORP·Filed 2020·Application pending·0 cites
- 4442US2017247476A1Protease-activatable bispecific proteinsAMGEN INC·Filed 2015·Application pending·0 cites
- 4541US2023137351A1Bispecific or biparatopic antigen binding proteins and uses thereofAMGEN INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Wei Yan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →